S2R agonists CB-64D and CB-184 inhibit cancer cell growth in both drug-sensitive MCF-7 and drug-resistant tumor cell lines, such as MCF7/AADR, SKBR3, and T47D, and induce apoptosis in these tumor cells in a dose-dependent manner [45]. Here, TMEM97 is linked to neoplasm.